Acute bipolar presentations include manic, hypomanic, mixed, and depressive states. manic presentations cannot be contained in a primary care setting and require psychiatric assessment for hospitalisation. Several drugs that have mood stabilising actions are now available, providing more treatment options for clinicians. Antidepressant use in bipolar depression remains controversial, but if considered clinically appropriate must be administered with a drug that stabilises mood. Psychosocial interventions help patients with recovery and to cope with residual symptoms of illness.
Introduction
Patients with bipolar disorders face significant risks of morbidity and mortality and present medical practitioners with considerable diagnostic and management challenges. The lifetime prevalence of bipolar disorders is estimated at 1-4% of the general population. 1 Suicide is attempted by 25-50% of sufferers 2 , and overall 15% of people with bipolar disorders die by suicide. 3 Accurate diagnosis depends on recognising often underreported symptoms of elevated mood. Mixed states (combined depressive and elevated symptoms) and comorbid substance misuse frequently cloud the initial diagnosis. These diagnostic complexities along with often impaired patient insight lead to a third of Australian patients suffering illness for more than ten years before accurate diagnosis is made and appropriate treatment given. 4 
Bipolar disorders
These are characterised by episodic depressions and elevations of mood. Bipolar I involves manic symptoms which last for at least a week and are severe enough to markedly impair functioning or require hospitalisation. In contrast, bipolar II involves hypomania in which elevated symptoms are less severe but still clearly different from usual mood and last for at least four days. In both forms of the illness, depressive episodes tend to be more frequent and disabling than mania. Sufferers spend 32-50% of follow-up in depressive episodes and only 1-9% in elevated states. 5 Most patients have inter-episode periods of recovery, but over 90% relapse without medications. 6 
Risk assessment
It is necessary to determine the most appropriate settings for patient care, and assess for suicidal ideations by examining past history of self-harm, current ideation, substance abuse, and the level of social supports.
In elevated and mixed states, the possibility of risk taking, impulsive behaviours, irritability, violence and misadventure must be considered. Where risks are deemed high, the patient needs more assertive care, and referral to psychiatric inpatient services is appropriate. Application of the relevant state mental health act may be required. Manic episodes cannot be contained in a general practice or community setting.
Given the diagnostic and management challenges of bipolar disorder, psychiatric confirmation of diagnosis and management advice is advisable. For patients with low to moderate risk, their initial care will usually be provided by their general practitioner, who has a pivotal role in assessment, diagnosis, referral and ongoing care.
Treatment
The goal of treatment in bipolar disorder is to stabilise mood. Symptomatic and specific maintenance medications are available for the acute treatment of bipolar disorders.
However, maintenance medication remains the cornerstone of management -both for acute episodes and maintenance treatment. 7 In recent years several new drugs have shown efficacy for the control of manic symptoms and prevention of relapse, but not all are approved for use in bipolar disorders. 8 Trialling medications in the acute phase of the illness -depressed, mixed, hypomanic and manic episodes -helps to find the most effective and tolerable drug or drugs necessary to achieve and maintain euthymic mood in individual patients.
In Australia, several effective drugs for bipolar disorders are subsidised by the Pharmaceutical Benefits Scheme, but some drugs require private prescriptions for use (see Table 1 ).
Manic episodes
Drugs recommended for the treatment of manic episodes are listed in Table 1 . 8, 9 Lithium, certain anticonvulsants 10 Approximately 50% of patients with mania will respond to monotherapy with any antimanic drug, and around 70-75% will respond to combination therapy. The longer-term evidence on such combination therapy remains limited, and while monotherapy is preferable from compliance, tolerability and cost perspectives, only a third of patients achieve longer-term mood stability on monotherapy. 11 Combination therapy is pragmatically the norm. In rare treatment-resistant cases of mania, where even multiple medications fail to control mania, electroconvulsive therapy and in some cases clozapine may need to be trialled. 12 Acute treatment is generally the start of maintenance therapy.
Hypomanic episodes
Due to the shorter duration of hypomanic episodes, and the lack of marked impairment, hypomania is less frequently the presenting symptom of the illness. Patients with hypomania may feel energetic and creative, and may not need much sleep.
They are unlikely to present complaining of feeling 'too well'.
In clinical practice, treatments for manic states are effective in hypomania. Importantly, patients with only hypomanic but no manic episodes (bipolar II pattern) do not tend to progress to bipolar I manic states. Nonetheless, hypomanic episodes are a core precipitant of downward mood destabilisations into major depressive episodes, and thus warrant active treatment, even though depression is invariably the reason patients present for treatment in bipolar II disorder. 
Mixed episodes

Depressive episodes
Drugs for the treatment of bipolar depressive episodes are listed in Table 2 . 8, 9 The best current evidence for efficacy in bipolar depression exists for lithium, quetiapine and lamotrigine. 8 Antidepressants place patients at risk of switching to elevated This list is a composite of recent evidence-based reviews and consensus management guidelines for bipolar mania 8, 9 * indicates no Pharmaceutical Benefits Scheme subsidy for acute mania at time of writing † the efficacy of clozapine is decreased with smoking Should an antidepressant be needed, low-dose selective serotonin reuptake inhibitors are usually adequate and may have less propensity to induce elevated phases of the disorder. 14 As fluoxetine has a five-week washout period it is best avoided in bipolar conditions in case a manic, mixed or hypomanic mood switch necessitates cessation.
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